

VitamFero will be presenting its immunotherapy data about infection disease prevention in chicks at the Apicowplexa 2017 conference in Madrid, October 11 to 14.

These groundbreaking findings highlight the prophylactic benefits of one of VitamFero non-virulent live parasitic strains for preventing opportunistic infections in chicks. With this approach, VitamFero is proposing a potential alternative to intensive antibiotic use on large-scale farms.

Angers, France: October 9, 2017

VitamFero, a French veterinary biotech company specialized in creating and developing new prophylactic approaches based on non-virulent live Apicomplexan parasite strains, is announcing that, in conjunction with François-Rabelais de Tours University and France's national institute for agricultural research (INRA), it has achieved particularly promising results for preventing serious infections in chicks.

Its non-virulent live strain of *Toxoplasma gondii* has been successfully tested for preventing neonatal infectious diseases in chicks. These tests have covered not only parasitic, but also bacterial and viral infection. Strongly stimulating the innate immune system in young birds, this strain has shown that it can effectively alleviate the clinical symptoms following infections with *Eimeria* (coccidiosis), *Salmonella* (salmonellosis) or *Influenza* (flu).

Moving forward with a round of private fundraising aimed at reaching breakeven within the next few years, VitamFero is further strengthening the potential of its innovative immunotherapy platform to be able to address the major public health challenges involved with the need to: (i) feed a global human population of 10 billion people by 2050, while safeguarding our planet and its biodiversity, (ii) combat antibiotic resistance, and (iii) offer solutions to prevent potential future pandemics, such as avian flu, which represent a major public health threats.

Dr Mehdi Ellouze, veterinarian and head of VitamFero's Preclinical and Clinical Unit: *"While VitamFero has already widely demonstrated the benefits of its vaccine technology for ruminants, I am delighted to be able to share today the particularly encouraging results that, with my team, we have been able to achieve, for the first time, in poultry. These results very clearly highlight once again VitamFero's original immunotherapy approach opening new animal health development opportunities, in line with the One Health concept for human health"*.

About VitamFero

VitamFero S.A. is a French biotech company specialized in immunotherapy for animal health. Its goal is to create, develop and sell new biologics to prevent infectious diseases among livestock and to reduce the use of antibiotics. Its patented technologies, such as Toxo KO and Neo KO, are based on non-virulent live vectors expressing genes coding for selected relevant proteins for vaccine development. This technological platform is also used to develop vaccines protecting animals from infections that are the most economically devastating for breeders and the most dreadful for their ability to mutate into human infectious strains. Through its participation in the veterinary segment of the "One Health" approach, which integrates animal, human, and environmental health, VitamFero affirms its commitment to public health. Find out more on www.vitamfero.com

Contact

Calyptus - Mathieu Calleux - vitamfero@calyptus.net
VitamFero - Pascal Breton, Directeur Général - p.breton@vitamfero.com - Tél. : +33 (0)6 82 65 47 69